1
. Indeed, gene knockout experiments revealed substantial functional redundancy between CDK4 and CDK6 in vivo in most tissues 2 . Apart from that, CDK6 was shown to possess some unique, cyclin-independent transcriptional roles in haematopoietic cells 3 . The activity of CDK4 and CDK6 (referred to herein as CDK4/6) is controlled by several mechanisms: positively by association with D-type cyclins (cyclins D1-3) and negatively by binding to CDK inhibitors of the INK4 family (p16 INK4A , p15 INKB , p18 INK4C and p19
INK4D
) 4 .
Mitogenic factors
Growth-promoting factors (such as the epidermal growth factor) that induce intracellular mitogenic signalling pathways that are required for proliferation of normal cells. Cancer cells proliferate independently of mitogenic factors as a result of mutations in proteins in these signalling pathways or owing to constitutive activation of the cell cycle machinery.
Spindle assembly checkpoint
(SAC). A cell cycle checkpoint that monitors the correct attachment of the chromosomes to the mitotic spindle during metaphase. Its activation induces cell cycle arrest via inhibition of the anaphase-promoting complex/ cyclosome (APC/C).
Cyclin D-CDK4 and cyclin D-CDK6 complexes (referred to herein as cyclin D-CDK4/6) promote cell cycle progression by two major mechanisms 5 . First, they sequester p21 CIP1 and p27 KIP1 , two CDK inhibitors that bind to and prevent activation of cyclin E-CDK2 kinase
. Second, active cyclin D-CDK4/6 complexes phosphorylate various cellular targets, most importantly, the retinoblastoma tumour suppressor protein (RB, encoded by RB1) and the closely related proteins p107 (also known as RBL1) and p130 (also known as RBL2), thereby enabling E2F transcription factors to activate transcription of a plethora of genes involved in cell cycle progression from G1 into S phase, DNA replication, chromatin structure, chromosome segregation and the spindle assembly checkpoint (SAC). Among the E2F transcriptional targets are cyclins E1 and E2, which bind to and activate CDK2. Cyclin E-CDK2 complexes further phosphorylate RB, thereby initiating a positive feedback loop. In addition to these canonical cell cycle functions, D-type cyclins, CDK4 and CDK6 were shown or postulated to perform several non-canonical functions, some of which may be relevant for regulation of proliferation 6 .
The role of the CDK4/6-RB pathway in cancer. Components of the CDK4/6-RB pathway are commonly mutated in human cancers (FIG. 3a-c) . For example, the cyclin D1 gene (CCND1) represents the second most frequently amplified locus among all human cancer types 7 . CDK4 is amplified in 50% of glioblastomas 8 and is constitutively activated by a point mutation (R24C, which renders CDK4 insensitive to inhibition by INK4 family members) in melanomas 9 . Similarly, CDK6 is activated by genomic translocations in splenic marginal zone lymphomas 10 . Furthermore, the CDKN2A gene (which encodes the tumour suppressors p16 INK4A and p14 ARF ) represents the most frequently deleted locus in human cancers and its expression is also commonly silenced by promoter methylation 7 . Finally, deletion of RB1 occurs frequently in many tumour types and enables proliferation independently of cyclin D-CDK4/6 activity 7 .
To test the role of D-type cyclins and their catalytic partners CDK4 and CDK6 in tumorigenesis and tumour maintenance, various genetically engineered mouse models were developed (TABLE 1; Supplementary information S1 (table) ). For instance, introduction of a CDK4 point mutation found in human melanoma (R24C) into the mouse Cdk4 locus caused tumorigenesis in various tissues 11 and increased the susceptibility of these knock-in animals to carcinogen-induced melanoma formation 12 . Furthermore, transgenic mice engineered to overexpress cyclin D1 in mammary glands developed mammary hyperplasia and mammary carcinomas 13 . These results highlighted the oncogenic properties of D-type cyclins, CDK4 and CDK6. Surprisingly, however, carcinogeninduced skin tumorigenesis was compromised by expression of Ccnd3 or CDK6 in the skin of transgenic mice 14, 15 , whereas CCND1, Ccnd2 or CDK4 expression enhanced skin tumorigenesis as expected 14, 16, 17 . Conversely, mice lacking cyclin D1 were resistant to mammary cancer formation induced by some oncogenes -such as vHras (an oncogenic HRAS mutant with Nature Reviews | Cancer Mitogenic signals activate complexes of cyclins and cyclin-dependent kinases (CDKs) that promote progression from the G1 phase into S phase by phosphorylating (P) several cellular targets, including the retinoblastoma protein (RB). RB hyperphosphorylation attenuates its growth-suppressive properties and leads to activation of transcription by the E2F family of transcription factors. Growth-inhibitory signals antagonize G1-S progression by upregulating CDK inhibitors of the INK4 and CIP/KIP families. Progression through S phase and from G2 phase into mitosis (M phase) is also controlled by cyclin-CDK complexes, together with various other proteins, such as Polo-like kinase 1 (PLK1) and Aurora kinases (Aurora A and Aurora B). Cells can also exit the cell cycle and enter a reversible or permanent cell cycle arrest (G0 phase). In addition, DNA damage is sensed by several specialized proteins and triggers cell cycle arrest via checkpoint kinase 2 (CHK2) and p53 in G1 phase or via CHK1 in S or G2 phase. Purple ovals denote positive regulators of cell cycle progression and blue ovals denote negative regulators of cell cycle progression. P in dashed circle indicates dephosphorylation. CDC25, cell division cycle 25. • MYC • AP1
• β-catenin
• CCNA2
• CCNB1
• CDC25B
• PLK1
• AURKB P P P P P P ) in response to senescence-inducing or growth-inhibitory signals, such as transforming growth factor-β (TGFβ). Cyclin D-CDK4/6 complexes drive phosphorylation (P) of the retinoblastoma protein (RB). RB hyperphosphorylation releases E2F transcription factors, which activate transcription of a plethora of S phase-promoting genes, including cyclin E1 (CCNE1) and CCNE2. Cyclin E-CDK2 complexes are kept in an inactive state by interaction with inhibitor proteins p27 KIP1 and p21 CIP1 , which are regulated by growth-inhibitory signals and the p53-dependent G1 DNA damage checkpoint. Activation of cyclin E-CDK2 involves several mechanisms, including the sequestration of p27 KIP1 and p21 CIP1 by cyclin D-CDK4/6 complexes and phosphorylation of p27 KIP1 by cyclin E-CDK2 kinase. Active cyclin E-CDK2 complexes further phosphorylate RB, as well as many other targets, leading to entry of cells into S phase. b | During G2 phase, the MUVB complex associates with the forkhead box M1 (FOXM1) transcription factor and binds to promoters containing cell cycle genes homology region (CHR) elements, thereby inducing transcription of genes required for entry into and progression through mitosis (M phase), including B-type cyclins. Activation of cyclin B-CDK1 kinase requires phosphorylation of CDK1 at Thr161 by the cyclin H-CDK7 complex (which is known as the CDK-activating kinase (CAK)) as well as dephosphorylation (P in dashed circle) of Thr14 and Tyr15 on CDK1 by cell division cycle 25 (CDC25) family phosphatases. The inhibitory Thr14 and Tyr15 phosphorylations are driven by the protein kinases membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (MYT1) and WEE1, respectively. Activation of CDK1 is prevented in response to activation of the checkpoint kinase 1 (CHK1)-dependent G2 DNA damage checkpoint. Upon recovery from DNA damage, Polo-like kinase 1 (PLK1) is essential for reactivation of CDK1. Activation of cyclin A/B-CDK1 complexes is required and sufficient for entry into mitosis. Purple ovals denote positive regulators of cell cycle progression, blue ovals denote negative regulators of cell cycle transition. ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; AURKA, gene encoding Aurora A; BORA, activator of Aurora A; DHFR, dihydrofolate reductase; DREAM, multiprotein complex consisting of p107, p130, E2F4, E2F5, DP1 and MUVB; GSK3β, glycogen synthase kinase 3β; MCM, minichromosome maintenance complex.
Breast cancer
Breast cancer is commonly divided into three clinical subgroups: hormone receptor-positive (ER + or HR + ) breast cancer with expression of oestrogen receptor (ER) and/ or progesterone receptor (PR) and with normal ERBB2 expression; HER2 + breast cancer with ERBB2 amplification or overexpression; triple-negative breast cancer (TNBC) with low or absent expression of ER and PR and without ERBB2 overexpression.
G12R and A59T mutations) or Erbb2
V664E -but not others (such as Wnt1 and Myc) 18, 19 . Further studies revealed that at least for Erbb2 V664E , this requirement for cyclin D1 function crucially depended on the kinase activity of CDK4 . Ccnd3-null mice were resistant to NOTCH1 ICD -driven T cell acute lymphoblastic leukaemia (T-ALL) 23 , whereas Cdk6-knockout mice were resistant to lymphoma formation induced by constitutively active AKT 24 . Intriguingly, lung cancer driven by oncogenic Kras G12V exhibited selective sensitivity to CDK4 inhibition, as acute deletion (that is, conditional deletion after tumour formation) of Cdk4, but not of Cdk6 or Cdk2, induced senescence and prevented tumour progression 25 . Similarly, an acute and global ablation of Ccnd1 or pharmacological inhibition of CDK4/6 kinase activity in mice bearing Erbb2
V664E
-driven mammary tumours blocked cancer progression and triggered tumour cellspecific senescence without having any obvious effects on normal, non-transformed tissues 26 . Surprisingly, an acute and ubiquitous deletion of Ccnd3 or inhibition of CDK4/6 in mice with Notch1 ICD -driven T-ALL resulted in tumour cell-specific apoptosis, rather than senescence, although the mechanism for this response has not yet been elucidated 26, 27 . Collectively, these analyses revealed that individual D-type cyclins, CDK4 and CDK6 are required for tumour initiation, and that their continued expression is crucial for tumour maintenance. This is in stark contrast to normal, non-transformed tissues, in which shutdown of individual D-type cyclins or inhibition of CDK4/6 catalytic activity had no major effects 26 . In summary, these studies illustrate that tumours are frequently dependent on individual cyclins and CDKs and hence susceptible to their targeted inhibition, which is in noticeable contrast to the redundancy observed in most normal, non-transformed tissues 5 .
CDK2. This CDK is activated through its association with E-type or A-type cyclins. In the absence of mitogens, CDK2 complexes are held in an inactive state by association with a CDK inhibitor p27 KIP1 or p21 CIP1 . During late G1 phase, CDK2 activity increases as a result of E2F-mediated transcription of cyclin E (CCNE) genes, cyclin D-CDK4/6-mediated sequestration of p27 KIP1 and p21
CIP1
, as well as ubiquitin-mediated proteolysis of p27 KIP1 and p21 CIP1 following their phosphorylation by CDK2. In addition, CDK2 activity is inhibited by WEE1-mediated phosphorylation at Tyr15, and this inhibitory phosphorylation is removed by the cell division cycle 25 (CDC25) family of phosphatases 28 . Cyclin E-CDK2 complexes phosphorylate various proteins required for cell cycle progression, DNA replication and centrosome duplication 29, 30 . During S phase, cyclin E is rapidly degraded following F-box/WD repeat-containing protein 7 (FBXW7)-mediated ubiquitylation 31,32 and CDK2 associates with newly synthesized cyclin A2 to form active cyclin A-CDK2 complexes.
CDK2 mutations are rarely found in human cancers; however, the catalytic activity of CDK2-containing complexes is hyperactivated via several mechanisms. The CCNE1 locus is frequently amplified in human malignancies, for example, in ovarian cancer and breast cancer 33, 34 (FIG. 3d) . In some tumour types cyclin E over expression occurs as a result of loss-of-function mutations in FBXW7, a ubiquitin ligase component involved in cyclin E degradation 35, 36 . Alternatively, certain tumours express a hyperactive, truncated form of cyclin E1 (REF. 37). Similarly, cyclin A is frequently overexpressed, sometimes as a result of genomic amplification, for example, in hepatocellular carcinomas 38 and colorectal 39 and breast cancers 40 . In some tumours CDK2 activity is enhanced following reduced expression of the CDK inhibitor p27 KIP1 , for example, due to increased S-phase kinase-associated protein 2 (SKP2)-mediated degradation 41 . In addition, CDC25A and CDC25B are overexpressed in various tumours [42] [43] [44] . These various mechanisms of CDK2 activation have been validated using mouse cancer models. Thus, transgenic overexpression of CCNE1 in mammary glands led to mammary cancer formation 45 . Increased activity of cyclin E-CDK2 resulting from deletion of genes encoding CDK inhibitor proteins p27 KIP1 or p21 CIP1 also increased the susceptibility to tumour formation 46, 47 
. Transgenic overexpression of CDC25A or CDC25B enhanced v-HRAS-induced, ERBB2-V664E-induced and carcinogen-induced mammary cancer formation 48, 49 . Conversely, hetero zygous deletion of Cdc25a delayed v-HRAS-induced and ERBB2-V664E-induced mammary tumorigenesis 50 . It is not clear whether CDK2 activity is required for tumour initiation and maintenance. Several human cancer cell lines were shown to proliferate despite inhibition of CDK2 activity 51 . Likewise, mice lacking CDK2 displayed unperturbed tumorigenesis in several tissues 25, [52] [53] [54] . However, MYC-overexpressing tumours were shown to require CDK2-mediated phosphory lation of MYC to suppress senescence 55, 56 . Indeed, deletion of Cdk2 delayed tumour formation in a mouse model
Box 1 | Cyclin-dependent kinase inhibitor proteins and their role in cancer
The activity of cyclin-dependent kinases (CDKs) is also regulated by their association with cyclin-dependent kinase inhibitors (CKIs). These include members of the INK4 family (p16   INK4A   , p15   INK4B   , p18  INK4C and p19   INK4D ), which bind to CDK4 and CDK6 and block their association with D-type cyclins, thereby extinguishing the kinase activity of CDK4 and CDK6. By contrast, CKIs from the CIP/KIP family (p21 CIP1 , p27 KIP1 and p57
KIP2
) bind to all cyclin-CDK complexes and primarily inhibit the kinase activity of CDK2 and CDK1.
As expected from their role as negative regulators of the cell cycle, CKIs display certain tumour-suppressive properties. Expression of INK4 proteins, in particular p16
INK4A and p15 INK4B (encoded by CDKN2A and CDKN2B, respectively), is silenced in human tumours by genomic deletions, loss-of-function point mutations or promoter methylation (FIG. 3a) . Furthermore, p27
KIP1 expression is frequently downregulated as a result of enhanced protein degradation in human tumours, an event associated with poor survival [246] [247] [248] , although deletion of its genomic locus (CDKN1B) is only rarely observed 249 . Several mouse models were generated to address the role of CKIs in tumorigenesis. For example, mice deficient for p16 INK4A spontaneously developed tumours and exhibited increased susceptibility to carcinogen-induced neoplasia 250 . Similarly, mice lacking p21
CIP1 exhibited an increased frequency of spontaneous tumours in various tissues 47 . Interestingly, mice heterozygous for Cdkn1b (encoding p27 KIP1 ) displayed increased susceptibility to tumorigenesis following exposure of animals to γ-radiation or chemical carcinogens, but did not exhibit loss of the remaining wild-type allele, indicating a haploinsufficient tumour suppressor role for this CKI 46 . These findings illustrate that CKIs generally function as tumour suppressors, presumably by restricting uncontrolled CDK activity and thereby serving as an additional barrier to malignant transformation.
Anaphase-promoting complex/cyclosome (APC/C). An E3 ubiquitin ligase complex that targets mitotic cyclins and other mitotic regulators for proteasomal degradation to enable chromosome segregation during metaphase-to-anaphase transition. It contains the F-box protein cell division cycle 20 (CDC20) (APC/C CDC20 ), which is later replaced by CDH1 (APC/ C CDH1 ) to maintain APC/C activity during mitotic exit and G1 phase.
of Myc-overexpressing B cell lymphoma (Eμ-Myc mice) 55 . Moreover, CDK2 depletion suppressed cell cycle progression in melanoma cells 57 . Also, mouse cancer models showed that CDK2 is crucially required for mammary cancer formation induced by overexpression of Erbb2 V664E or a cancer-associated truncated CCNE1 isoform 37, 58 . Hence, CDK2 function may be required in specific cancer types.
CDK1.
CDK1 is the only CDK that is essential for cell cycle progression 59 . During G2 phase, CDK1 binds to and becomes activated by cyclin A2 and cyclin B. Upon entry into mitosis, cyclin A2 is degraded and CDK1 activity is maintained in complexes with B-type cyclins; CDK1 kinase activity is required for mitotic entry and several mitotic events. B-type cyclins are degraded by the anaphase-promoting complex/cyclosome (APC/C) in late mitosis 60 . This extinguishes CDK1 activity and enables chromosome separation and completion of mitosis and cytokinesis. In addition to regulation by its cyclin partners, CDK1 activity is inhibited by phosphorylation at Thr14 and Tyr15, mediated by the kinases membraneassociated tyrosine-and threonine-specific cdc2-inhibitory kinase (MYT1; also known as PKMYT1) 61 and WEE1 (REF. 62 ), respectively; this phosphorylation is relieved by CDC25 phosphatases 62 (FIG. 2b) . Interestingly, CDK1 activity is rarely deregulated in cancer, one of the few examples being CCNB3 gene amplifications in neuroendocrine prostate cancer 63 . Transgenic overexpression of Ccnb1 or Ccnb2 increased susceptibility to carcinogen-induced skin and lung tumours, revealing a potential role for elevated CDK1 activity in tumorigenesis 64 . Moreover, CDK1 has been shown to be required for tumour formation and progression. For example, liver-specific ablation of Cdk1 conferred resistance to NRAS-G12V-induced liver tumorigenesis 65 , and CDK1 inhibition blocked the growth of KRAS-mutant (G12V, G12D or G12S) colorectal cancer xenografts 66 . However, CDK1 activity is essential for proliferation also in normal, non-transformed cells 59 , arguing against inhibition of CDK1 as a viable therapeutic strategy. Intriguingly, inhibition of CDK1 triggered apoptosis of MYC-driven mouse lymphomas and liver tumours 67 , as well as human basal-like triple-negative breast cancer cells 68 . These findings raise a possibility that CDK1 inhibition might specifically kill tumour cells, while causing only transient cell cycle arrest in normal tissues, a notion that requires further investigation using genetic mouse models.
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DNA damage checkpoint kinases and WEE1. Cells have checkpoints to halt cell cycle progression in response to DNA damage, thereby allowing time for DNA repair. Several DNA damage checkpoints exist and they impinge on the activity of specific CDK complexes (FIG. 1) . Depending on the type of DNA damage, ataxia telangiectasia and Rad3-related (ATR) or ataxia telangiectasia mutated (ATM) protein kinases phosphorylate and activate checkpoint kinase 1 (CHK1, encoded by the CHEK1 gene) 69 . Similarly, ATM can also activate CHK2 (encoded by CHEK2), which in turn participates in the activation of p53 (REF. 70 ). Activation of p53 transcriptionally induces expression of the CDK inhibitor p21 CIP1 , leading to inhibition of cyclin E-CDK2 complexes and G1 arrest 71 
(FIG. 2a).
Activated CHK1 mediates temporary S phase arrest by phosphorylating and inactivating CDC25A and G2 checkpoint arrest by phosphorylating CDC25A, CDC25B and CDC25C 72, 73 . These events prevent dephosphorylation of Tyr15 on CDK2 and CDK1, thereby rendering these CDKs inactive. CHK1 also activates WEE1 via direct phosphorylation, leading to enhanced inhibitory Tyr15 phosphorylation of CDK2 and CDK1 and subsequent cell cycle arrest in G2 phase 74 (FIG. 2b) . In summary, CHK1 is an essential mediator of DNA damage-induced cell cycle arrest in S and G2 phases, particularly in cancer cells with inactivated p53, which depend on G2 checkpoint activation to halt cell proliferation.
The role of CHK1 and WEE1 in cancer development is controversial. CHK1 was initially regarded as a tumour suppressor. Indeed, heterozygous loss-of-function mutations of the CHEK1 locus were detected in breast 75 and gastric 76 cancers; however, no homozygous loss-of-function mutations have been identified so far. Consistent with these findings, heterozygous deletion of Chek1 in mice enhanced mammary tumorigenesis induced by the Wnt1 oncogene or by heterozygous deletion of Trp53 (which encodes p53 in mice) 77, 78 . By contrast, tissue-specific homozygous deletion of Chek1 in mice inhibited mammary tumorigenesis induced by Trp53 loss 78 and prevented carcinogen-induced skin tumour formation 79 . Consistent with an oncogenic role for CHK1, this protein is overexpressed in many cancers, for example, triple-negative breast cancer, hepatocellular carcinoma and cervical cancer [80] [81] [82] . Furthermore, an extra allele of Chek1 protected mouse fibroblasts from replicative stress and enhanced HRAS-G12V-induced transformation by reducing DNA damage-associated apoptosis in vitro 83 . Collectively, these observations suggest that although reduced CHK1 levels (resulting from heterozygous Chek1 deletion) may enhance tumorigenesis, CHK1 is required for tumour cell growth and survival by enabling DNA damage repair. In contrast to CHK1, CHK2 is thought to have a mostly tumour-suppressive role, as several loss-of-function mouse models exhibited enhanced tumorigenesis. Hence, CHK2 does not seem to represent a suitable target for cancer therapy (TABLE 1; Supplementary information S1 (table)).
WEE1 kinase is overexpressed in several cancer types, for instance, in hepatocellular carcinoma 84 , glioblastoma 85 and melanoma 86 . By contrast, hetero zygous deletion of Wee1 in the mammary gland induced spontaneous development of mammary cancer in a small percentage of older mice, whereas no tumours were observed upon homozygous deletion 87 . Hence, tumorigenesis may be incompatible with complete loss of WEE1 activity, similar to CHK1. Despite these contradictory results, WEE1 is generally considered to be an oncogene and a potential target in cancer therapy.
PLKs. The family of PLKs consists of five members, of which PLK1 has been studied in most detail. During G2 phase, PLK1 participates in the maturation of centrosomes by regulating the centrosomal localization of Aurora A 88 . Moreover, PLK1 has an important role in the activation of cyclin B-CDK1 complexes by at least two mechanisms. First, it activates CDC25C phosphatase, which in turn removes the inhibitory Tyr15 phosphorylation of CDK1 (REF. 89 ). Second, PLK1 induces phosphorylationdependent degradation of WEE1, thereby preventing further phosphorylation of CDK1 at Tyr15 (REF. 90) (FIG. 2b) . Subsequently, PLK1 is involved in triggering chromosome segregation during the metaphase-anaphase transition and has important roles in cytokinesis. PLK1 is also crucial for mitotic entry following recovery from DNA damage-induced G2 phase arrest, providing a rationale for its exploitation as a target in cancer therapy.
The role of PLK1 in cancer is not clear. PLK1 expression is frequently elevated in tumours, correlates with poor prognosis and is thought to contribute to tumorigenesis by compromising cell cycle checkpoints and inducing genetic instability [91] [92] [93] . By contrast, a few cancer cell lines exhibited mutations that reduce PLK1 stability 94 . Furthermore, heterozygous deletion of Plk1 in mice increased the incidence of spontaneous tumours, suggesting a potential tumour-suppressive role for PLK1 (REF. 95 ). Despite these conflicting results, PLK1 is generally considered oncogenic and a potential target in cancer therapy.
Aurora kinases. Aurora kinases are serine/threonine kinases with major roles in mitosis and cytokinesis. Aurora A localizes to the centrosomes, starting in S phase, and is essential for centrosome maturation, spindle assembly and spindle orientation. Furthermore, Aurora A phosphorylates and activates PLK1, thereby promoting CDK1 activation and mitotic entry, especially after DNA damage checkpoint-dependent G2 phase arrest 96, 97 . Aurora A also stabilizes the transcription factor NMYC (encoded by MYCN) by preventing its proteasomal degradation, and thereby promotes G1-S progression 98 . During mitosis, Aurora B is found at chromosomes and at the mitotic spindle where it constitutes a part of the chromosomal passenger complex (CPC). Aurora B controls chromosome condensation and orientation as well as proper execution of cytokinesis.
Ectopic overexpression of Aurora A caused inactivation of the DNA damage checkpoint during the G2 phase 99 and inactivation of the spindle assembly checkpoint during mitosis 100 , leading to tetraploidy and centrosome amplification, especially in cells with defective p53-dependent DNA damage checkpoints 101 . Also, overexpression of Aurora B caused defective chromosome separation, leading to aneuploidy 102 . Analyses of human tumours support oncogenic roles for Aurora A and Aurora B. The gene encoding Aurora A (AURKA) is frequently amplified in prostate 103 and breast 104 cancers, and several other cancer types express elevated levels of Aurora A protein 105 . Aurora B is also found overexpressed in several cancer types, although its genomic locus is rarely amplified, for example, in only 5% of myelodysplastic syndromes 106 . Importantly, transgenic overexpression of AURKA in mouse mammary epithelium induced tetraploidy and centrosome amplification, leading to the formation of mammary cancer 107 . Likewise, mice ubiquitously overexpressing Aurkb spontaneously developed lymphomas 102 . Surprisingly, despite their role as oncogenes, heterozygous deletion of Aurka and Aurkb in mice also increased tumour incidence in various organs, suggesting tumour-suppressive roles in certain tissues 108, 109 . 50 , inhibitor concentration that causes 50% inhibition of kinase activity (in vitro kinase assay); JAK2, Janus kinase 2; MDS, myelodysplastic syndromes; MELK, maternal embryonic leucine zipper kinase; NA, not available; PARP, poly(ADP-ribose) polymerase; PDGFR, platelet derived growth factor receptor; PLK, Polo-like kinase; RB, retinoblastoma; RSK1, ribosomal protein S6 kinase A1; SIK, salt-inducible kinase; siRNA, short interfering RNA; TAK1, TGFβ activated kinase 1; TIE2, tyrosine kinase with Ig and EGF homology domains 2; TRK, tropomyosin-related kinase; VEGFR, vascular endothelial growth factor receptor; YES1, YES kinase. *Intravenous; ‡ oral; § meeting abstract data.
Mitotic catastrophe
A particular form of apoptosis that occurs during mitosis as a result of aberrant chromosome segregation or DNA damage, typically related to inactivation of cell cycle checkpoints.
Synthetic lethality
With regard to cancer therapy, this concept postulates that inhibition of a specific protein is lethal for cancer cells harbouring a particular mutation while sparing normal cells without that mutation. As a result, drugs provoking synthetic lethality are expected to have a higher therapeutic index.
Pan-CDK inhibitors
Inhibitors of cyclin-dependent kinases (CDKs) with a broad specificity (that is, not selective for individual CDKs).
Clinical trials
New agents with promising preclinical results (animal models) are first tested for safety (adverse effects), optimal dosage and preliminary signs of efficacy (phase I), then for their efficacy using the optimal dosage in a defined, small group of patients (phase II) and, finally, in a large, randomized, double-blind study in comparison with a placebo or the current gold standard of treatment (phase III).
Therapeutic index
The ratio between the drug dose causing the desired pharmacological effect and the dose causing toxicity (for example, toxicity or lethality in 50% of patients or animals, respectively).
Rationale for targeting
Cell cycle proteins are frequently overactive in cancer cells, leading to uncontrolled proliferation. As we described above, global genetic ablation of individual cyclins or CDKs, or inhibition of cyclin-CDK kinase activity in tumour-bearing mice selectively blocked initiation and progression of specific cancer types driven by particular oncogenic insults, without having major effects on normal tissues. This suggests that tumour cells are dependent on (or 'addicted' to) specific CDKs, depending on the genetic lesions they carry, and hence, CDK inhibition may selectively target cancer cells while sparing normal tissues. In some instances, inhibition of CDK activity in mouse cancer models not only led to cell cycle arrest but also triggered tumour cell senescence or apoptosis. This indicates that particular tumours crucially depend on specific cell cycle proteins to inhibit tumour-suppressive programmes such as senescence and apoptosis, thereby rendering these cancer cells particularly vulnerable to inhibition of cell cycle proteins.
By contrast, inhibition of cell cycle proteins that are crucial for checkpoint function, such as CHK1 and WEE1, follows an opposite strategy. Cell cycle checkpoints are essential to halt cell cycle progression in response to DNA damage, thereby allowing time for DNA repair. Inhibition of CHK1 or WEE1 in cancer cells prevents cell cycle arrest during S or G2 phase and enables cell proliferation despite accumulation of DNA damage. This can lead to cell death during mitosis by a process sometimes referred to as mitotic catastrophe (REF. 110 ). This strategy applies particularly to cancer cells with compromised G1 checkpoint due to loss of p53 function, as these cancer cells crucially depend on the G2 checkpoint, especially in the presence of DNA damage-inducing drugs. For this reason, inactivation of p53 renders cancer cells particularly sensitive to inhibition of CHK1 or WEE1, an example of so-called synthetic lethality.
Targeting CDKs in cancer therapy
Development of pan-CDK inhibitors. Most of the early compounds exhibited little specificity towards individual CDKs and are therefore commonly referred to as pan-CDK inhibitors. The first generation of these inhibitors includes flavopiridol (also known as alvocidib) and R-roscovitine (also known as seliciclib).
Flavopiridol is a semisynthetic flavone that inhibits many CDKs, and it represents the most extensively studied CDK inhibitor, with more than 60 clinical trials initiated since 1997 (TABLE 2; Supplementary information S2 (table) ). It causes cell cycle arrest in G1 and G2 phases 111 . Administration of flavopiridol induced apoptosis in several mouse tissues, leading to organ atrophy 112 , an effect attributed to inhibition of cyclin T1-CDK9 (this complex is also known as P-TEFb) kinase 113 . Although flavopiridol exhibited significant antitumour activity in preclinical studies 112 , clinical phase II studies reported insufficient efficacy for solid cancers. However, some evidence of clinical activity was observed in haemato logical malignancies 114, 115 (TABLE 3;  Supplementary information S3 (table) ).
By contrast, R-roscovitine did not show promising antitumour activities in preclinical and clinical studies as monotherapy; nevertheless, R-roscovitine is still under clinical investigation in combination with chemotherapy for solid tumours (meeting abstract 116 ). In general, first-generation pan-CDK inhibitors suffered from a low therapeutic index, leading to toxicities at concentrations necessary to inhibit their targets. To circumvent these limitations, second-generation pan-CDK inhibitors were developed; these include dinaciclib, AT7519, milciclib (also known as PHA-848125AC), TG02, CYC065 and RGB-286638 (TABLE 2; Supplementary  information S2 (table)) .
Dinaciclib is a CDK inhibitor with more than 100-fold higher potency in inhibiting RB phosphorylation and a more than 10-fold higher therapeutic index than flavopiridol 117 ( . This synergy most likely resulted from the combined inhibition of multiple KRAS effector pathways (RAL and PI3K-AKT) in these KRAS-driven tumours. Finally, dinaciclib treatment may be efficacious in MYC-overexpressing triple-negative breast cancer and MYC-driven B cell lymphomas, as it caused tumour regression and enhanced survival in preclinical mouse models 68, 128 . Currently, an ongoing phase I study is investigating the use of dinaciclib in treating patients with MYC-overexpressing solid cancers 129 .
Development and clinical success of CDK4/6-selective inhibitors.
Following promising results from genetic and preclinical studies, the first group of CDK-selective compounds to enter the clinics were the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib 130 . (table) ). As expected, palbociclib prevents RB phosphorylation by cyclin D-CDK4/6 and causes cell cycle arrest in G1 phase 132 . Consistent with the notion that RB represents the major rate-limiting target of CDK4/6 during cell cycle progression, cells that 
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• 151 ) and CDK4-amplified liposarcoma 152 . In all these studies, adverse effects of palbociclib included neutropenia (reduced number of neutrophil granulocytes) and thrombocytopenia. The former probably represents an on-target off-tumour effect, as genetic ablation of Ccnd3, the major D-type cyclin in haematopoietic cells, results in severe neutropenia in mice 153 . The randomized phase II clinical trial PALOMA-1 compared treatment with palbociclib and letrozole (a standard-of-care inhibitor of aromatase, an enzyme that is responsible for a key step in oestrogen biosynthesis) with treatment with letrozole alone for postmenopausal women with previously untreated ER + ERBB2-non-amplified (HER2 − ) advanced breast cancer. The addition of palbociclib strongly increased the median progressionfree survival (PFS) from 10.2 months to 20.2 months 154 . The median overall survival (OS) was also improved with the combination treatment, although a larger study needs to evaluate whether this is statistically significant. On the basis of these results, palbociclib received accelerated (that is, provisional) approval from the US Food and Drug Administration (FDA) in February 2015 (REF. 155 ). A phase III study (PALOMA-2) was initiated to validate the clinical benefit of this treatment (see Supplementary information S4 (table) ). Furthermore, a randomized, doubleblind, placebo-controlled phase III trial, PALOMA-3, compared treatment with palbociclib and fulvestrant (an ER antagonist) with treatment with placebo and fulvestrant for women with ER + HER2
− metastatic breast cancer that has relapsed or progressed during prior hormonal therapy, including a substantial proportion of patients (33%) who had received prior chemotherapy for metastatic disease. The interim analysis of this study demonstrated a significantly improved median PFS (9.5 months for palbociclib and fulvestrant versus 4.6 months for placebo and fulvestrant) 156, 157 . Although an analysis of OS is not yet possible, this second-line treatment for metastatic breast cancer received approval from the FDA in February 2016 (REF. 158 ). Palbociclib is currently being studied in more than 50 clinical trials involving a wide variety of cancer types (TABLE 2; Supplementary information S2 (table)). Improvement of the clinical outcome will depend on identification of predictive biomarkers. So far, only ER (in breast cancer) and RB expression have shown some value in predicting positive outcome and are used in clinical trials, whereas CCND1 amplification 154, 159 , CDKN2A loss 154, 159 , PIK3CA mutation 157 and RB localization 159 were not informative.
Ribociclib also selectively inhibits CDK4 and CDK6 with high potency 160 (TABLE 2; Supplementary  information S2 (table) ). Similarly to palbociclib, it blocks RB phosphorylation and causes cell cycle arrest of tumour cells 161 . Furthermore, ribociclib showed antitumour activity in xenografts of neuroblastoma (including senescence induction) 161 , liposarcoma 143 , rhabdomyosarcoma 145 and Ewing sarcoma 162 . The first clinical phase I trial involving various advanced RB + cancers reported partial responses in a patient with CCND1-amplified, PIK3CA-mutated breast cancer and a patient with CCND1-amplified melanoma; the major dose-limiting toxicities were neutropenia and thrombocytopenia (meeting abstract 163 ). Ribociclib was then studied in combination with hormonal therapy for postmenopausal women with ER + HER2
− advanced breast cancer and exhibited preliminary signs of clinical activity (meeting abstract 164 ) ( Abemaciclib inhibits not only CDK4 and CDK6 but also several other kinases -albeit with a lower potency -including CDK9 and PIM1 (REF. 165) (TABLE 2;  Supplementary information S2 (table) ). Similarly to palbociclib and ribociclib, it inhibits RB phosphorylation and causes cell cycle arrest in the G1 phase. Abemaciclib demonstrated antitumour activity in xenograft models of colorectal cancer 165 , AML 165 and melanoma 166 . Furthermore, systemically administered abemaciclib crossed the blood-brain barrier more efficiently than palbociclib and blocked tumour progression in an orthotopic glioblastoma xenograft model 167 . The first phase I trial for patients with various types of advanced cancer reported responses in three patients (with ovarian cancer, KRAS-mutant NSCLC or CDKN2A-deleted, NRASmutant melanoma) (meeting abstract 168 ). The major adverse effects were fatigue, neutropenia and diarrhoea. Further studies evaluated abemaciclib as monotherapy for patients with advanced NSCLC that has relapsed or progressed during previous treatment (TABLE 3; Supplementary information S3 (table) ). Partial responses were observed in only 2% of patients but an additional 49% achieved stable disease (meeting abstract 169 ). Whether this improves PFS and OS is currently under investigation in a large phase III trial (JUNIPER; see Supplementary information S4 (table)). In another study, 23% of patients with metastatic breast cancer showed partial responses to abemaciclib monotherapy (meeting abstract ). The clinical benefit of this combination treatment is currently being validated in a large phase III trial (MONARCH 3).
Several studies investigated the value of combining CDK4/6 inhibitors with additional compounds. A phase I study investigated the utility of combining palbociclib with paclitaxel, a microtubule stabilizer, and showed partial responses in 40% of patients with RB + metastatic breast cancer (meeting abstract 173 ). The combined inhibition of MEK and CDK4 had a synergistic effect and led to tumour regression in several preclinical mouse models of NRAS-mutant melanoma 174 . The potential value of this combination was then evaluated in a small phase Ib/II trial (meeting abstract 175 ). Indeed, combination of ribociclib and the MEK inhibitor binimetinib resulted in partial responses in 43% of patients with NRAS-mutant melanoma. Furthermore, resistance of PIK3CA-mutant breast cancer to PI3Kα inhibition was attributed to increased CDK4/6 activity 176 . Indeed, combination of PI3Kα and CDK4/6 inhibition caused synergistic tumour regression in several PIK3CA-mutant breast cancer xenograft models 176 . The efficacy of combining ribociclib with a PI3Kα inhibitor (BYL719) and an aromatase inhibitor (letrozole) is currently being investigated in a phase Ib study for advanced ER + breast cancer (meeting abstract 164 ). Finally, following an increase in efficacy revealed by preclinical studies, combination of ribociclib with an mTOR inhibitor (everolimus) and an aromatase inhibitor (exemestane) is also currently under clinical investigation in ER + breast cancer (meeting abstract 177 ). These results illustrate that therapeutic improvement frequently depends on combined inhibition of CDK4/6 and other signalling pathways that are overactive in certain tumours. It is likely that the combined treatment induces a permanent cell cycle arrest (senescence) or cell death instead of a transient cell cycle arrest, which is commonly observed with CDK4/6-directed monotherapy.
Paradoxically, combination of palbociclib with conventional chemotherapeutic agents decreased their antitumour activity 178, 179 . These results were observed only in RB + tumours and can be explained by the fact that palbociclib induces G1 arrest of cancer cells, thereby protecting them from the cytotoxic action of chemotherapeutic agents. These results caution against combining CDK4/6 inhibitors with chemotherapy for RB + tumours. Importantly, administration of CDK4/6 inhibitors was shown to protect normal bone marrow cells from the effects of cytotoxic drugs or radiotherapy, by reducing the proliferation of haematopoietic progenitor cells 178, 180 . Hence, this chemoprotective effect of CDK4/6 inhibition might be valuable in reducing haematological toxicities of chemotherapy or radiotherapy in patients bearing CDK4/6-independent (for example, RB -) tumours and it is currently being investigated in a clinical trial 181 . In contrast to the observations described above, combination of palbociclib with radiotherapy showed enhanced efficacy in a xenograft model of RB + glioblastoma 139 . This suggests that CDK4/6 inhibitors may be combined successfully with radiotherapy in certain cases, although the mechanism and applicability to other tumours are currently unknown.
On the basis of experience with other targeted cancer therapeutics, it is expected that tumour cells will eventually develop resistance to CDK4/6 inhibition. Although the molecular basis is currently unknown, possible mechanisms include the loss of RB expression, overexpression of cyclin D1, CDK4 or E2F, hyperactivation of cyclin E-CDK2 kinase via cyclin E over expression or the loss of CDK inhibitor p21 CIP1 or p27 KIP2 , as well as overexpression of certain ABC transporters. However, further work is needed to delineate the molecular events that lead to acquired resistance of tumour cells to CDK4/6 inhibition.
Targeting of other cell cycle proteins
Inhibitors of CHK1 and WEE1. During the past decade, several CHK1 and WEE1 inhibitors have been developed and tested in preclinical and clinical studies. Currently, three of them seem promising: CHK1 inhibitors MK-8776 (also known as SCH 900776) and LY2606368 (also known as prexasertib) and the WEE1 inhibitor AZD1775 ( 182 . Furthermore, it synergized with gemcitabine, hydroxyurea and cytarabine in causing apoptosis of AML and breast cancer cells in vitro, as well as with gemcitabine in ovarian and pancreatic cancer xenografts [182] [183] [184] . On the basis of these studies, the first clinical phase I trial with MK-8776 in combination with gemcitabine was initiated for patients with advanced solid tumours. The trial showed preliminary activity and little toxicity 185 . Another phase I clinical trial investigated the sequential administration of cytarabine and MK-8776 in patients with relapsed or refractory acute leukaemia. This combination achieved complete response in 33% of patients 186 ( 190 . AZD1775 synergized with various chemotherapeutic compounds as well as with radiotherapy and was particularly effective against tumours with a defective G1 phase DNA damage checkpoint due to loss of p53 function, an example of synthetic lethality [190] [191] [192] . Treatment with AZD1775 (either alone or together with chemotherapy or radiotherapy) achieved promising antitumour activity in xenograft models of pancreatic cancer, NSCLC, AML and glioma [193] [194] [195] [196] . Moreover, WEE1 and PARP inhibition synergistically increased radiosensitivity in a xenograft model of pancreatic cancer 197 . AZD1775 also acted synergistically with inhibitors of histone deacetylases (HDACs) both in vitro and in xenograft models of AML and pancreatic cancer 198, 199 . Furthermore, combined WEE1 and mTOR inhibition achieved tumour regression in a mouse model of KRAS
G12D
-induced lung cancer as well as in xenografts of KRAS A18D -expressing AML 200 . Finally, combined WEE1 and CHK1 inhibition induced DNA damage and apoptosis in the absence of chemotherapeutics and inhibited tumour growth in neuroblastoma xenografts 201, 202 Rigosertib is a multi-kinase inhibitor with highest affinity for PLK1 (REF. 205 ). Rigosertib caused tumour regression in a xenograft model of head and neck squamous cell carcinoma 206 and, in combination with radiotherapy, in xenografts of cervical cancer 207 . Clinical trials focused mainly on pancreatic cancer and myelodysplastic syndromes (MDS). Whereas treatment with rigosertib and gemcitabine did not improve survival of patients with pancreatic cancer (TABLE 4; Supplementary information S5 (table)), the outcomes for patients with MDS were more promising. In patients with higher-risk MDS, an analysis of four clinical phase I/II trials reported bone marrow responses in 40% and cyto genetic responses in 6% of patients 208 . Rigosertib was then compared with best supportive care for patients with higherrisk MDS, who have either relapsed after, failed to respond to or progressed during treatment with hypomethylating agents (HMAs), in a randomized phase III trial (ONTIME). Prolonged median OS was observed for a subgroup of patients with primary HMA treatment failure (8.6 months versus 4.5 months) (meeting abstract 209 ), as well as for another subgroup of patients characterized by very poor prognosis (7.6 months versus 3.2 months) (meeting abstract 210 • PR: 27% ( • Neutropenia (32%)
(as monotherapy) 213 , ALL (as monotherapy and in combination with cytarabine or quizartinib) 213, 214 , breast cancer (in combination with fulvestrant) 215 and rhabdomyosarcoma (with vincristine) 216 . A phase II trial compared volasertib in combination with low-dose cytarabine with cytarabine alone for older patients with AML ( [218] [219] [220] . Future clinical application will depend on identification of biomarkers that can predict clinical response. On the basis of in vitro data it was Please refer to Supplementary information S5 (table) for a version of this table with references. AML, acute myeloid leukaemia; b.i.d., twice daily; CR, complete response; CRi, complete response with incomplete recovery; EFS, event-free survival; HMA, hypomethylating agent (azacitidine or decitabine); HR, hazard ratio; i.v., intravenous administration; MDS, myelodysplastic syndromes; n, number of patients; NA, not available; OS, overall survival; P, P value of two-sided statistical test; P/C, paclitaxel and carboplatin; PFS, progression-free survival; p.o., oral administration; PR, partial response; q.i.d., once daily; RP2D, recommended phase II dose; RR, overall response rate (complete + partial responses); s.c., subcutaneously; SD, stable disease; vs, versus. *Meeting abstract data.
Event-free survival
(EFS). The time from the start of cancer treatment until the occurrence of defined events such as certain complications or the recurrence of cancer.
suggested that p53 − cancers would be particularly sensitive to PLK1 inhibition because these cancer cells demonstrated increased expression of several genes involved in the G2-M transition, including PLK1, and increased sensitivity to PLK1 inhibition 221 . Importantly, overexpression of the ABC transporter ABCB1 (also known as P-glycoprotein) conferred resistance to volasertib treatment in vitro, supporting future co-administration of ABCB1 inhibitors to improve clinical responses 222 .
Inhibitors of Aurora kinases. Several inhibitors targeting the major family members Aurora A and Aurora B, such as alisertib, ENMD-2076, danusertib and AMG-900, have been developed and are under clinical investigation (TABLE 2; Supplementary information S2 (table) ). Conversely, a selective Aurora B inhibitor, barasertib (also known as AZD1152), was discontinued after several clinical phase II trials showed no substantial clinical benefit.
Alisertib exhibits high selectivity for Aurora A 223 . Treatment of cancer cells with alisertib was shown to induce mitotic arrest and polyploidy, and resulted in senescence or apoptosis 224, 225 . Monotherapy with alisertib showed tumour regression in preclinical mouse models of neuroblastoma 226 , ALL 226 and lymphoma 223 . Interestingly, Aurora A inhibition using alisertib triggered degradation of NMYC and hence caused tumour regression in a MYCN-driven mouse model of neuroblastoma 227 . Furthermore, combination of alisertib with chemotherapeutics induced tumour regression in mouse models of AML 228 , oesophageal cancer 229 and gastric cancer 230 . Alisertib also synergized with inhibitors of BCR-ABL (in chronic myeloid leukaemia) 231 , CD20 (in mantle cell lymphoma 232 and diffuse large B cell lymphoma 233 ), MEK (in colorectal cancer) 234 and BCL-2 (in neuroblastoma) 235 , as well as with an agonist of the cell death receptor DR5 (also known as TNFRSF10B; in melanoma) 236 . The first clinical phase I trial involving alisertib monotherapy started in 2007 and reported a partial response in a patient with refractory ovarian cancer 237 . Although alisertib monotherapy did not achieve sufficient clinical activity in a subsequent phase II trial for patients with platinum-resistant or refractory ovarian cancer 238 , an ongoing phase I/II study reported an encouraging response rate of 29% in combination with paclitaxel for patients with recurrent ovarian cancer (meeting abstract 239 ) (TABLE 4; Supplementary information S5 (table) ). Furthermore, another phase II study for solid tumours showed promising activity for patients with small cell lung carcinoma (response rate 21%) and breast cancer (response rate 18%) 240 . Combination with docetaxel demonstrated good preliminary activity in castration-resistant prostate cancer (response rate ~50%) (meeting abstract 241 ) and in combination with bortezomib (a proteasome inhibitor) in multiple myeloma (response rate 27%) 242 . Moreover, two phase II studies reported promising antitumour activity in relapsed or refractory B cell and T cell non-Hodgkin lymphoma (response rate 27%) 243 and in relapsed or refractory peripheral T cell lymphoma (response rate 30%) 244 .
The potential clinical benefit for patients with peripheral T cell lymphoma is now being investigated in a phase III trial (Supplementary information S4 (table) ). Alisertib is currently being studied in more than 30 clinical trials involving a wide variety of cancers (TABLE 2;  Supplementary information S2 (table) ). Although alisertib showed impressive preclinical results and evidence of clinical activity, it is currently unknown whether this will translate into improved patient survival compared with currently available treatments. Furthermore, a better understanding of molecular determinants of alisertib sensitivity may improve therapeutic success.
Conclusions
Although basic cell cycle regulators were discovered more than 30 years ago, the past decade has seen a dramatic increase in our understanding of their role in cancer and their potential as targets for cancer therapy. The development of novel compounds enabled cell cycle studies to be brought from bench to bedside. Indeed, the provisional approval of a CDK4/6-selective inhibitor (palbociclib) for breast cancer treatment by the FDA represents the first successful clinical translation in this field. Other CDK4/6-selective inhibitors demonstrated very encouraging results and their approval is expected within the next few years. Inhibitors that selectively inhibit CDK4 but not CDK6 (and vice versa) may also be developed, and they could possibly reduce adverse effects without compromising therapeutic benefit. Furthermore, CDK2-and CDK1-selective inhibitors will probably be developed, as they may have clinical use for specific cancer subtypes 55, [66] [67] [68] . The success of future cell cycle-targeted therapies will depend on the development of selective and potent compounds and on the identification of specific vulnerabilities of cancer cells. Cell culture-based screening approaches, patient-derived xenografts and genetically engineered mouse models of cancer will probably remain essential for uncovering synthetic lethal interactions between genomic lesions and selective inhibition of individual cell cycle proteins. It should be noted that current targeted therapies suffer from a relatively low percentage of patients showing satisfactory, long-term response. Hence, genomic technologies will become an invaluable diagnostic tool to identify patient subsets that respond best to a given targeted therapy. Novel treatment modalities that can target multiple components of the same pathway, such as microRNAs (miRs), may also help to achieve a more sustained therapeutic benefit. Indeed, MRX34, a miR-34 mimic that targets multiple cell cycle gene transcripts, recently entered clinical phase I evaluation 245 . Combination of several selective inhibitors may substantially improve the response; however, combination therapies often increase adverse effects and may thus not be tolerated by many patients. Finally, as many preclinical studies as well as clinical experience indicate the occurrence of resistance (that is, relapse after an initial response), research on resistance mechanisms against current compounds will help to identify treatment options for patients with relapsed or refractory disease, and suggest combinatorial therapies that might prevent acquisition of resistance.
